NIQ Debuts Growth Pathways: Transforming How Brands Create Growth
9.4.2026 13:00:00 CEST | Business Wire | Press Release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, announces the launch of NIQ Growth Pathways, a next-generation insights and analytics offering that modernizes traditional research and gives business leaders and marketers a clearer and structured route for category and brand growth. By integrating qualitative and quantitative research with NIQ’s industry-leading performance data, Growth Pathways delivers a connected view of how consumers think, feel, and act.
In today’s shifting consumer landscape, where global CPG volume growth has stagnated at under 1% annually, brand marketers need clarity on where to source demand, which opportunities matter most, and how to focus resources that will accelerate penetration and strengthen brand preference. Traditional strategies no longer meet the needs of today’s environment, as consumer behavior evolves and market dynamics grow increasingly complex.
NIQ’s Growth Pathways creates a growth relevant roadmap relevant for your brand and your market context, by linking your current performance reality – your actual sales performance, with consumer insights and future performance projections, into an expedited and actionable roadmap to achieve market growth. Fast AI enabled qualitative research at scale reveals the real, lived human Jobs to Be Done and behavioral context that sit behind category and brand choice. This provides an accurate starting point for sizing and prioritizing the high-value strategic spaces where your brand has the right-to-play. This all comes together as a strategic playbook for either category, or brand growth, or both.
“When brands look beyond familiar boundaries and consider the full range of choices consumers actually weigh in and beyond your category, new growth possibilities come into view,” said Stacy Bereck, NIQ Global Practice Leader. “Growth Pathways helps teams notice opportunities in places they may not have explored previously, which inspires new ways of thinking about growth. As brands innovate and enter new spaces, they can energize the entire category.”
The launch of Growth Pathways reflects NIQ’s ongoing transformation and commitment to delivering AI-enabled, open-data, client-first solutions. With more than 23,000 clients across 90+ countries, 22.2M store coverage, 220M product categories and collaboration programs across more than 50 retailers worldwide, NIQ continues to build a faster, smarter, and more connected insights ecosystem—empowering leaders with predictive intelligence that fuels growth across the global marketplace.
“More than ever before, companies need to make fewer but bigger brand bets in order to grow, and those bets must be consumer driven, evidence-based, and scalable,” said Gillian O'Sullivan, NIQ Global Sub-Practice Leader. “Growth Pathways takes validated marketing methods and applies them in a structured scientific KPI framework to determine the right pathway to sizeable and sustainable brand growth.”
To explore NIQ Growth Pathways or request a demo, click here.
FAQs
1. What is NIQ Growth Pathways?
NIQ Growth Pathways is an AI-enabled consumer insights and analytics solution that helps brands identify, prioritize, and activate new sources of growth. It combines consumer research, retail measurement data, and advanced analytics to deliver a structured growth strategy for brands and categories.
2. What does NIQ Growth Pathways do?
NIQ Growth Pathways helps companies:
- Identify untapped growth opportunities
- Understand consumer behavior (what consumers think, feel, and do)
- Prioritize high-value demand spaces
- Build actionable growth strategies based on data
It translates complex data into clear, decision-ready growth pathways.
3. How does NIQ Growth Pathways use AI?
NIQ Growth Pathways uses AI to scale qualitative research and uncover deep consumer insights, including motivations, unmet needs, and “Jobs to Be Done.” AI accelerates insight generation, improves accuracy, and enables faster identification of growth opportunities.
4. What makes NIQ Growth Pathways different from traditional market research?
Unlike traditional market research, NIQ Growth Pathways:
- Integrates qualitative insights, quantitative data, and sales performance
- Connects past performance with future growth projections
- Uses AI to analyze consumer behavior at scale
- Delivers a structured, actionable growth roadmap instead of static reports
5. What problem does NIQ Growth Pathways solve for brands?
NIQ Growth Pathways helps brands solve the problem of low growth and unclear demand signals in modern markets. With global CPG growth under 1%, brands need better tools to identify where to grow, how to win, and which investments will deliver the highest return.
6. Who should use NIQ Growth Pathways?
NIQ Growth Pathways is designed for:
- Brand managers
- Marketing leaders
- Consumer insights teams
- Strategy and innovation teams
It is especially useful for organizations making large, strategic, data-driven growth decisions.
7. What industries can use NIQ Growth Pathways?
NIQ Growth Pathways is primarily built for FMCG and CPG companies but can be applied to any consumer-focused industry that relies on understanding buying behavior, demand drivers, and market dynamics.
8. What are “growth pathways” in NIQ Growth Pathways?
“Growth pathways” are data-driven, prioritized routes to growth. They are based on:
- Current brand and category performance
- Consumer needs and behaviors
- Competitive and market dynamics
- Future growth potential
Each pathway represents a strategic opportunity that a brand can act on.
9. How does NIQ Growth Pathways identify growth opportunities?
NIQ Growth Pathways identifies growth opportunities by combining:
- Retail and sales performance data
- Consumer research (qualitative and quantitative)
- AI-driven insight generation
- Advanced analytics
This creates a holistic view of where demand exists and where it can be expanded.
10. How does NIQ Growth Pathways help brands grow beyond their category?
NIQ Growth Pathways analyzes the full set of consumer choices, not just those within a single category. This helps brands discover adjacent markets, new use cases, and emerging white spaces where they have the right to compete and grow.
11. What are the key benefits of NIQ Growth Pathways?
Key benefits include:
- Identification of new and untapped growth opportunities
- Faster, AI-powered insights
- Clear prioritization of strategic investments
- A structured, repeatable growth framework
- Alignment between insights, strategy, and execution
12. How does NIQ Growth Pathways fit into NIQ’s capabilities?
NIQ Growth Pathways is built on NIQ’s global data, AI, and analytics platform, including:
- Retail measurement and consumer panel data
- AI modeling and advanced analytics
- Global coverage across 90+ countries
- Insights across $7.4 trillion in consumer spend
13. When was NIQ Growth Pathways launched?
NIQ Growth Pathways was announced on April 9, 2026, as part of NIQ’s continued investment in AI-enabled, client-first innovation.
14. How can companies access NIQ Growth Pathways?
Companies can access NIQ Growth Pathways by contacting NIQ or requesting a demo through www.niq.com.
About NIQ
NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.
With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.
For more information, please visit www.niq.com.
Forward Looking Statement:
This press release on NIQ Growth Pathways may contain forward looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” “plan,” “look ahead,” “indicates”, and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.
© 2026 Nielsen Consumer LLC. All Rights Reserved.
NIQ-GENERAL
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409909932/en/
Contacts
Media Contact:
NIQ:media.relations@niq.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom